Redhill Biopharma Ltd. (NASDAQ:RDHL) Short Interest Down 43.1% in August

Redhill Biopharma Ltd. (NASDAQ:RDHL) was the recipient of a large drop in short interest in the month of August. As of August 31st, there was short interest totaling 8,372 shares, a drop of 43.1% from the August 15th total of 14,705 shares. Approximately 0.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 9,188,161 shares, the short-interest ratio is currently 0.0 days.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Redhill Biopharma in a report on Monday, August 3rd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Redhill Biopharma presently has a consensus rating of “Sell”.

Redhill Biopharma Stock Performance

RDHL opened at $0.61 on Tuesday. Redhill Biopharma has a one year low of $0.57 and a one year high of $2.79. The stock’s fifty day moving average is $0.67 and its 200-day moving average is $0.82. The company has a market capitalization of $3.73 million, a PE ratio of 0.00 and a beta of 4.96.

Institutional Investors Weigh In On Redhill Biopharma

An institutional investor recently raised its stake in Redhill Biopharma stock. Gagnon Securities LLC raised its holdings in Redhill Biopharma Ltd. (NASDAQ:RDHL) by 383.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 86,102 shares of the biotechnology company’s stock after acquiring an additional 68,280 shares during the quarter. Gagnon Securities LLC owned 1.68% of Redhill Biopharma worth $89,000 as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 7.20% of the company’s stock.

Redhill Biopharma Company Profile

RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of proprietary, orally-administered small molecules for the treatment of inflammatory, gastrointestinal and oncology indications. Founded in 2009 and headquartered in Tel Aviv, Israel, RedHill is publicly traded on the Nasdaq under the symbol RDHL. The company’s strategy centers on in-licensing late-stage clinical candidates and advancing them through regulatory review toward global commercialization.

RedHill’s lead marketed product, Talicia® (formerly RHB-105), is an FDA-approved, three-drug treatment for Helicobacter pylori infection, co-commercialized in the United States through a partnership with Bausch Health.